TG
ALXN

TCW Group’s Alexion Pharmaceuticals ALXN Stock Holding History

TCW Group’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-347,381
Closed -$31.2M – 321
2020
Q1 		$31.2M Sell
347,381
-64,004
-16% -$6.28M 0.43% 61
2019
Q4 		$44.5M Sell
411,385
-38,197
-8% -$4.09M 0.49% 65
2019
Q3 		$44M Sell
449,582
-57,717
-11% -$6.51M 0.5% 64
2019
Q2 		$66.4M Sell
507,299
-9,376
-2% -$1.21M 0.71% 52
2019
Q1 		$69.8M Sell
516,675
-286
-0.1% -$35.6K 0.67% 60
2018
Q4 		$50.3M Sell
516,961
-50,950
-9% -$6.02M 0.52% 64
2018
Q3 		$78.9M Sell
567,911
-2,821
-0.5% -$354K 0.65% 58
2018
Q2 		$70.9M Sell
570,732
-26,553
-4% -$3.1M 0.57% 69
2018
Q1 		$66.6M Sell
597,285
-53,475
-8% -$6.39M 0.54% 69
2017
Q4 		$77.8M Sell
650,760
-57,361
-8% -$6.99M 0.63% 61
2017
Q3 		$99.3M Sell
708,121
-21,146
-3% -$2.87M 0.79% 52
2017
Q2 		$88.7M Sell
729,267
-24,627
-3% -$2.87M 0.74% 52
2017
Q1 		$91.4M Sell
753,894
-329,534
-30% -$42.5M 0.76% 56
2016
Q4 		$133M Sell
1,083,428
-40,397
-4% -$4.94M 1% 39
2016
Q3 		$138M Sell
1,123,825
-25,039
-2% -$3.22M 1.05% 33
2016
Q2 		$134M Buy
1,148,864
+39,690
+4% +$5.63M 1.01% 35
2016
Q1 		$154M Sell
1,109,174
-227
-0% -$33.3K 1.13% 26
2015
Q4 		$212M Buy
1,109,401
+4,457
+0.4% +$779K 1.52% 13
2015
Q3 		$173M Buy
1,104,944
+54,345
+5% +$9.91M 1.24% 21
2015
Q2 		$190M Sell
1,050,599
-49,648
-5% -$8.57M 1.22% 21
2015
Q1 		$191M Buy
1,100,247
+372,822
+51% +$67.5M 0.92% 31
2014
Q4 		$135M Buy
727,425
+621,495
+587% +$115M 0.56% 64
2014
Q3 		$17.6M Buy
105,930
+2,150
+2% +$353K 0.07% 223
2014
Q2 		$16.2M Buy
103,780
+800
+0.8% +$126K 0.07% 241
2014
Q1 		$15.7M Sell
102,980
-3,119
-3% -$496K 0.07% 238
2013
Q4 		$14.1M Buy
106,099
+629
+0.6% +$75.5K 0.06% 263
2013
Q3 		$12.3M Buy
105,470
+800
+0.8% +$87.8K 0.06% 269
2013
Q2 		$9.65M Buy
+104,670
New +$10.1M 0.05% 310

Other funds holding ALXN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

TCW Group's ALXN Position: Q2 2020 in Review

TCW Group sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 347,381 shares — an estimated $31.2M sold.

TCW Group first reported a position in ALXN in Q2 2013 and held it in 28 quarters. The position peaked at $212M in Q4 2015. 705 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

  • TCW Group reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • TCW Group sold 347,381 Alexion Pharmaceuticals shares in Q2 2020, an estimated $31.2M.
  • TCW Group first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 28 quarters.
  • TCW Group's Alexion Pharmaceuticals position peaked at $212M in Q4 2015.
  • 705 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on TCW Group's 13F filing for Q2 2020, filed 5 Aug 2020.